Opportunity Assessment
Validate clinical demand for AI diagnostics in a new market. Covers radiologist and pathologist interviews, hospital IT assessment, regulatory mapping, and a Go/Defer/Kill recommendation.
Learn more →
Our POV · 2026
Digital diagnostics and ai pathology market entry strategy
Digital diagnostics and AI pathology are transforming clinical decision-making – with AI-powered image analysis, digital slide scanning, automated cytology, and AI radiology all achieving clinical validation and commercial deployment. Digital pathology platform developers, AI radiology companies, and diagnostic AI solution providers are all evaluating new market entry opportunities as hospitals seek to address pathologist and radiologist shortages with AI-augmented diagnostics. GreyRadius helps digital diagnostics businesses validate clinical demand, navigate regulatory requirements, execute GTM plans, and raise capital.
Why now? Pathologist and radiologist shortages are a global healthcare system crisis – the WHO estimates a shortage of 2.4 million healthcare workers by 2030, with diagnostic specialists among the most acutely shortage-affected. AI diagnostics that can address this shortage are receiving accelerated regulatory approval and hospital procurement attention in Southeast Asia, South Asia, and the Gulf.
Market Intelligence
What the data says.
AI medical imaging market is projected to reach $20B by 2030 – growing at 30%+ annually as FDA, CE, and Asian regulatory approvals accelerate and hospital technology investment increases.
Digital pathology adoption is accelerating in Southeast Asian and South Asian hospitals – whole slide imaging scanners and AI analysis platforms are being deployed to address pathologist shortages and reduce turnaround times.
AI radiology is achieving clinical accuracy comparable to specialist radiologists for specific conditions – chest X-ray analysis, mammography screening, and diabetic retinopathy detection are all commercially deployed in multiple markets.
Remote diagnostic reading is growing – AI-assisted teleradiology platforms are enabling specialist interpretation of imaging from rural and secondary hospitals by radiologists in metropolitan centres.
Market Reality
What makes this market hard.
- Regulatory approval as a medical device is required in most markets – AI diagnostic tools classified as Software as a Medical Device require clinical performance studies, regulatory dossiers, and local registration.
- Hospital IT integration is complex – AI diagnostic tools must integrate with PACS, LIS, and HIS systems that vary significantly across hospitals, requiring significant technical integration investment.
- Physician acceptance of AI diagnostics is mixed – some clinicians embrace AI as a diagnostic aid while others resist AI-generated recommendations, requiring clinical champion development strategies.
- Evidence generation requirements are high – hospitals and insurers require clinical study data demonstrating diagnostic accuracy and patient outcome improvement before widespread deployment.
Our Work
What we solve for clients.
If you recognise your situation below, we can help.
Clinical demand validation
You need to validate that hospitals and clinical laboratories in your target market are actively seeking AI diagnostic solutions and what their evidence and integration requirements are.
Regulatory SaMD classification and pathway
You need to understand how your AI diagnostic tool is classified and what clinical performance data is required for regulatory approval.
Hospital and laboratory partner identification
You need to identify reference hospitals and diagnostic laboratories that will provide clinical validation and serve as early customers.
GTM for an AI diagnostics platform
You have an AI radiology, pathology, or diagnostics tool and need a go-to-market strategy covering hospital and laboratory acquisition.
Raising capital for a digital diagnostics venture
You are raising investment and need a pitch book grounded in clinical validation data and market sizing.
Competitive intelligence
You need to understand how competing AI diagnostics companies are positioned and winning hospital contracts in your target market.
Our Services
How we engage.
Every engagement is grounded in primary research and delivers a measurable outcome.
Feasibility & TEV
Full financial and operational feasibility for digital diagnostics investments. Covers hospital adoption modelling, integration cost structure, revenue model, and investor-ready projections.
Learn more →
Market Entry Execution
End-to-end market entry for digital diagnostics companies. Regulatory SaMD pathway, reference hospital identification, and first-hospital clinical validation.
Learn more →
GTM Execution-as-a-Service
Embedded GTM team for AI diagnostics platforms. Hospital outreach, clinical champion engagement, and first-commercial-deployment milestone.
Learn more →
Pitchbook & Fundraising
Investor-ready pitch books for digital diagnostics ventures. Clinical-evidence-validated market sizing and investor identification.
Learn more →
AI Consulting
AI strategy and use-case prioritisation – identifying which diagnostic conditions and clinical workflows offer the fastest path to clinical validation and commercial deployment.
Learn more →Why GreyRadius.
Primary research-led
80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Expert-led, AI-enabled delivery
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
Outcomes, not reports
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Case Studies
Mandates we've run.
Diagnostics · Market Entry
Market entry for a diagnostics chain into 3 Gulf markets
Regulatory mappedSite surveyPartnership model
View all case studies →
Diagnostics · Assessment
Opportunity assessment for a home-diagnostics platform in India
Consumer researchCompetitor mappedUnit economics
View all case studies →
Diagnostics · GTM
GTM for a point-of-care diagnostics device in Southeast Asia
Distributor networkFirst contractsClinical validation
View all case studies →
FAQ
Common questions.
Does GreyRadius work with AI radiology companies or also with digital pathology and diagnostic AI? +
All three. We work with AI radiology, digital pathology, and broad diagnostic AI companies across market entry, GTM, and fundraising.
What digital diagnostics markets does GreyRadius cover? +
Southeast Asia, South Asia, and the Gulf – markets with significant diagnostic workforce shortages and hospital technology investment.
How long does a digital diagnostics market entry engagement take? +
Typically 8–12 weeks given the complexity of regulatory pathway mapping and clinical stakeholder research.
Can GreyRadius identify reference hospital partners for AI diagnostics companies? +
Yes. Reference hospital identification and initial clinical discussions are part of our market entry execution service.
Stay informed
Market intelligence for diagnostics leaders.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Related market entry guides
Ready to enter this market?
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Southeast Asia, South Asia, Gulf.
Book a call